Skip to main content
European Commission logo
Live, work, travel in the EU
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

Scientific literature on COVID-19 Test Methods and Devices - detail

Cross-Comparison of a Chemiluminescent Platform and a Commercial Receptor Binding Domain-Based ELISA Assay for Detecting SARS-CoV-2 IgG

DOI
10.1093/jalm/jfaa133 
Detection Principle
ImmunoAssay-Antibody
Target
IgG, IgM
Testing Method Category
Other Immuno assay
Testing Method
Abbott Architect IgG assay, GenScript SARS-CoV-2 Spike S1-RBD IgG ELISA
Testing Method - Additional Info
Parallel Architect and ELISA analyses were performed
Reported Performance
Architect specificity: serum 100%; plasma 98.8%. ELISA treshold 1 specificity: serum 85.7%; plasma 93.5% ; treshold 2: serum 66.7%; plasma 92.9%. Architect sensitivity: serum 90.5%; plasma 93.5%. ELISA treshold 1 sensitivity: serum 85.7%; plasma 93.5%; treshold 2: serum 66.7%; plasma 82.6%
Sample Size
230 serum + 238 plasma
Peer-reviewed
yes

The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements